DCLK1 has also been associated with drug resistance in colorectal cancer, pancreatic cancer, and kidney cancer (Ge et al. 2018; Makino et al. 2020; Qu et al. 2019). This evidence concerns the gene DCLK1 and pancreatic neoplasm.